Company / SG&A Expense
Zivo Bioscience, Inc. SG&A Expense History
FY2013-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$10.3M
FY2024
5-year range
$4.8M / $10.3M
FY2020-FY2024
Trend
+74.2%
vs FY2023
Sector context
Sector data unavailable
Latest sector comparison
What the data says
SG&A Expense returned to growth in FY2024 after 2 years of decline, reaching $10M.
Based on SEC 10-K filings.
$10M in FY2024 with a 10-year CAGR of +25.8%.
Increased from $6M to $10M over the past 2 years.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +15.4%
- 5-Year CAGR
- +20.3%
- 10-Year CAGR
- +25.8%
Key checks
Key Insights
- 5-year CAGR of +20.3%, indicating consistent growth.
- In FY2024, sg&a expense increased 74.2% year-over-year.
- Lowest sg&a expense in the period was in FY2016.
Company context
Key Data Points
- Altman Z-Score -96.05 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $10.3M | +74.2% |
| FY2023 | $5.9M | -9.2% |
| FY2022 | $6.5M | -3.0% |
| FY2021 | $6.7M | +38.9% |
| FY2020 | $4.8M | +18.3% |
| FY2019 | $4.1M | +389.8% |
| FY2016 | $832.2K | -13.6% |
| FY2015 | $963.3K | -7.0% |
| FY2014 | $1.0M | -12.9% |
| FY2013 | $1.2M | +26.8% |
As of FY2024 · SEC 10-K · Updated Jun 29, 2026